(S)-1-(3-fluoro-4-(trifluoromethoxy)phenyl)-3-(1-(2-methylbutanoyl)piperidin-4-yl)urea: Applied Strategies in Signaling Pathway and Redox Biology Research

Principle Overview: Mechanistic Foundations and Product Attributes

(S)-1-(3-fluoro-4-(trifluoromethoxy)phenyl)-3-(1-(2-methylbutanoyl)piperidin-4-yl)urea, also known as BPN-19186, is a next-generation fluorinated phenyl urea compound that is redefining the landscape of small molecule inhibitor research. With a molecular weight of 405.39 and the unique structural motif combining a fluorinated phenyl group with a piperidinyl urea backbone, this compound is engineered for precise modulation of signaling pathways and enzyme inhibition, particularly within the contexts of cancer biology, neuroscience, and metabolic bone disease.

Its high solubility in organic solvents (≥52.1 mg/mL in DMSO, ≥54.9 mg/mL in ethanol) and stringent purity (96.42–98.00% by HPLC and NMR) make it ideal for demanding biochemical workflows. The compound’s stability profile—solid state storage at -20°C and prompt use after dissolution—ensures reproducibility in both in vitro and in vivo applications. APExBIO, a trusted supplier, provides this reagent with comprehensive documentation (COA, MSDS) and blue ice shipping for quality assurance.

Mechanistically, BPN-19186 has proven utility in disrupting enzyme activities—such as soluble epoxide hydrolase (sEH)—and modulating redox-sensitive signaling axes like the Nrf2-antioxidant response element (ARE) pathway, as recently detailed in a seminal Free Radical Biology and Medicine study.

Experimental Workflow: Step-by-Step Protocol Enhancements

1. Compound Preparation and Handling

• Weigh the desired amount of BPN-19186 under anhydrous conditions to prevent hydrolysis.
• Dissolve in DMSO or ethanol to prepare a stock solution, targeting concentrations between 10–50 mM depending on assay requirements.
• Vortex and, if necessary, sonicate briefly to ensure complete dissolution (solubility ≥52.1 mg/mL in DMSO; ≥54.9 mg/mL in EtOH).
• Filter sterilize using a 0.22 μm PTFE filter for cell-based assays.
• Aliquot and store at -20°C; avoid repeated freeze-thaw cycles. Use within 48 hours of initial solubilization for optimal stability.

2. Enzyme Inhibition and Signaling Pathway Assays

• Enzyme Inhibition Studies: Incorporate BPN-19186 at 0.01–10 μM final concentrations in enzymatic assays (e.g., sEH, caspases, or other proteases) to dissect dose-response dynamics. Use appropriate negative (vehicle) and positive controls.
• Signaling Pathway Modulation: For Nrf2-ARE or related pathway activation, treat cultured cells (e.g., osteoclast precursors, neuronal lines, or cancer cells) with 1–5 μM BPN-19186 and harvest at 2–24 hours for downstream transcriptomic or proteomic analysis.
• Validate pathway modulation using western blot (Nrf2, Keap1, HO-1), qPCR, or ARE-luciferase reporter assays.

3. Disease Model Integration

• In in vivo osteoporosis models (e.g., ovariectomized mice), administer BPN-19186 via intraperitoneal injection (dosed at 10–30 mg/kg, as inferred from dose titration studies) to evaluate effects on osteoclastogenesis and bone microarchitecture.
• Quantify plasma 14,15-EET and 14,15-DHET levels via LC-MS/MS to confirm sEH inhibition.
• Assess downstream cytokine profiles (e.g., TNF-α, IL-6) and bone resorption markers for functional validation.

Advanced Applications and Comparative Advantages

BPN-19186’s distinctiveness lies in its dual utility as a small molecule inhibitor for biochemical research and a probe for redox and signaling pathway modulation. Recent advances, as illuminated by Liu et al. (2025), demonstrate that sEH inhibition by BPN-19186 can restore redox balance and suppress osteoclast differentiation by activating the Nrf2-ARE axis. In their robust study, sEH inhibitors like BPN-19186 normalized circulating 14,15-EET/14,15-DHET ratios and reduced pro-inflammatory cytokines, thus reversing osteoporosis phenotypes in preclinical models.

Key comparative advantages include:

• Superior Solubility: Outperforms many conventional small molecule inhibitors, enhancing assay throughput and consistency.
• High Purity and Lot Traceability: Essential for reproducibility in both basic and translational research.
• Mechanistic Breadth: Effective in a range of models—from cancer biology (MAPK, caspase signaling pathway) and neuroscience (synaptic redox modulation) to metabolic bone disease (osteoclastogenesis via Nrf2 regulation).

These attributes are underscored in this mechanistic deep-dive, which complements the current protocol-driven focus by detailing BPN-19186’s unique ability to dissect osteoclastogenesis through Nrf2 pathway targeting. For a systems biology perspective that extends the current workflow to redox regulation, see this analysis. Meanwhile, a practical roadmap for translational deployment—bridging in vitro findings to in vivo disease models—is available in this thought-leadership piece, further reinforcing APExBIO’s SKU A8959 as a cornerstone for advanced signaling research.

Troubleshooting and Optimization Tips

Common Challenges and Solutions

• Incomplete Dissolution: If the compound does not fully dissolve in DMSO or ethanol, gently warm the solution (≤37°C) and vortex; avoid prolonged heating that could induce degradation.
• Precipitation in Aqueous Media: As BPN-19186 is water-insoluble, ensure that DMSO/ethanol stock solutions are diluted into culture medium with constant mixing. Keep final organic solvent concentration ≤0.1% to minimize cytotoxicity.
• Stability Concerns: Prepare fresh solutions before each experiment. For multi-day assays, consider daily supplementation to maintain effective concentrations.
• Batch Variability: Always reference the Certificate of Analysis (COA) for each lot and verify purity via HPLC or NMR as needed.
• Assay Interference: Include appropriate vehicle controls, and if unexpected results arise, confirm compound integrity via mass spectrometry.

Performance Optimization

• For enzyme inhibition studies, calibrate IC50 values by generating full dose-response curves (e.g., 0.01–100 μM range) and cross-validate with orthogonal assay formats.
• In cell-based signaling pathway assays, optimize treatment windows (2–24 h) and verify pathway activation/inhibition using downstream markers (e.g., Nrf2 nuclear translocation, caspase cleavage).
• For in vivo models, titrate dosing regimens and monitor pharmacokinetics to maximize on-target engagement while minimizing off-target effects.

Future Outlook: Expanding the Utility of BPN-19186

The unique chemical architecture of BPN-19186 positions it as a next-generation tool for dissecting redox-regulated signaling networks across diverse biological contexts. Ongoing research is exploring its translational potential in cancer therapy (e.g., targeting the MAPK and caspase signaling pathways), neuroprotection (via Nrf2/antioxidant modulation), and metabolic bone disorders. The recent elucidation of the liver-bone axis and sEH’s role in osteoclastogenesis (see Liu et al., 2025) exemplifies the compound’s capacity to drive paradigm shifts in our understanding of inter-organ communication and disease etiology.

Looking ahead, integration with high-throughput screening, multi-omics analysis, and advanced in vivo models will further expand the utility of BPN-19186 as a fluorinated phenyl urea compound. As the research community continues to unravel the intricacies of signaling pathway modulation and protease inhibition, APExBIO’s SKU A8959 stands ready to enable reproducible, high-impact discoveries in both basic and translational domains.

For more details or to order, visit the (S)-1-(3-fluoro-4-(trifluoromethoxy)phenyl)-3-(1-(2-methylbutanoyl)piperidin-4-yl)urea product page at APExBIO.